Clinical trials
Hematologic Diseases clinical trials
Below are recruiting hematologic diseases clinical trials, each written for real people, not researchers. We’re tracking 238 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT07689630RecruitingPhase 3
Antibody to prevent GVHD in half-matched stem cell transplant
This study is testing whether giving a special antibody (anti-CD25) before a half-matched stem cell transplant can prevent a common side effect called graft-versus-host disease (GVHD), where donor cells attack your body. It is for people with blood cancers who are getting this type of transplant.
Wuhan, HubeiAges 18–75 - NCT05444348Recruiting
Communication and care-planning support for blood cancer patients
This study tests an approach to help people with certain blood cancers and their main caregiver plan ahead and communicate more clearly about end-of-life care. It may help patients feel more supported and better prepared for difficult decisions.
AalborgAges 18 years+ - NCT05196789Recruiting
Genetic testing to diagnose inherited bone marrow failure
This study looks at patients with suspected inherited (families-linked) bone marrow failure to better understand the cause using genetic testing. It may help confirm a diagnosis and refine how different inherited conditions are classified.
Melbourne, VictoriaAges 3 months+ - NCT04662294RecruitingEarly Phase 1
CD70-targeted CAR T therapy for CD70-positive blood cancers
This trial tests a customized immune-cell treatment (CAR T) that targets CD70 on cancer cells in certain blood cancers. It may help people whose disease has returned or did not respond to standard treatments.
Hangzhou, ZhejiangAges Any age - NCT04640987RecruitingPhase 1
Stem cell transplant with added T-cells for blood cancers
This Phase 1 study tests a stem cell transplant plan that uses donor T-cells that have been specially processed and then added back. It aims to see if this approach is safer and works better for children and adults with serious blood cancers who need a transplant.
Palo Alto, CaliforniaAges 1 month–45 years - NCT07724873RecruitingPhase 1/Phase 2
Withaferin A to prevent GVHD after stem cell transplant
This study tests a natural compound called Withaferin A (from ashwagandha) to see if it helps prevent graft-versus-host disease (GVHD) after a stem cell transplant. The goal is to reduce the risk of transplant complications.
Navi Mumbai, MaharashtraAges 18 years+ - NCT04249830Recruiting
Donor stem cell transplant after donor cell targeting in youth
This trial studies a special donor stem cell transplant where the donor’s immune cells are reduced, aiming to lower harmful immune attacks after transplant. It may help children and young adults with certain high-risk blood cancers or rare bone marrow disorders.
Palo Alto, CaliforniaAges 1 month–60 years - NCT03844360RecruitingPhase 4
Personalized dosing of cancer or infection medicines in children
This trial looks at how to adjust the dose of cancer medicines and/or anti-infection medicines in children who have blood-related cancers. The goal is to make dosing fit each child’s needs while they receive standard treatment.
Xuzhou, JiangsuAges 1 day–18 years - NCT00186147Enrolling by invitation
Bone marrow grafting for leukemia and lymphoma
This study involves bone marrow cell grafting for people affected by leukemia or lymphoma. You may be eligible if you are a transplant recipient or a donor and you freely choose to take part.
Stanford, CaliforniaAges 18–70 - NCT07624370Enrolling by invitation
Frailty Assessment in Older Adults with Cancer
This study evaluates how to better assess and manage frailty (age-related weakness and vulnerability) in older cancer patients aged 70 and up who are starting chemotherapy or other cancer treatments. The goal is to help doctors tailor treatment plans to each patient's individual strength and health status.
Legnano, ItalyAges 70 years+ - NCT07441525RecruitingEarly Phase 1
CAR-T cell therapy for hard-to-treat autoimmune blood diseases
This early-stage trial tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and BCMA, in people with autoimmune blood diseases like ITP, AIHA, or Evans syndrome that have not responded to standard treatments. It aims to reset the immune system and reduce production of harmful antibodies.
Wuhan, HubeiAges 18–75 - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT06880419RecruitingPhase 2
Anti-CD25 antibody to prevent graft-versus-host disease in high-risk adults
This trial tests whether an antibody called anti-CD25 can help prevent a serious side effect (graft-versus-host disease) in adults getting a stem cell transplant for blood disorders. It is for people considered high-risk based on a special scoring model.
Tianjin, Tianjin MunicipalityAges 16 years+ - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT07234110Recruiting
CD5 CAR-T therapy for returning blood cancers
This trial tests a new treatment using your own immune cells, modified to find and attack cancer cells that have a CD5 marker. It may be an option for people with certain lymphomas or leukemia that have not responded to standard treatments or have come back.
Tianjin, Tianjin MunicipalityAges 1–70 - NCT07185503Recruiting
Testing two antifungal drugs for mucormycosis with blood cancer
This trial tests a combination of two antifungal medications (liposomal amphotericin B and posaconazole or isavuconazole) to treat a serious fungal infection called mucormycosis in people with blood cancers like leukemia or lymphoma. The goal is to see if this combination is safe and works well.
DalianAges 18–65 - NCT07109518RecruitingPhase 1
CD7 CAR T-Cell Therapy for Blood Cancers That Return or Don't Respond
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07153068RecruitingPhase 1/Phase 2
SupCD7 CART therapy for CD7 positive blood cancers
This trial tests a special immune cell therapy (SupCD7 CART) that targets a protein called CD7 on cancer cells. It is for people with certain types of blood cancers (like T-ALL/LBL or AML) that have come back or not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06793475Recruiting
Aponermin before CAR-T for multiple myeloma with extramedullary disease
This trial tests whether a drug called aponermin, given before CAR-T cell therapy, can help people with multiple myeloma that has come back or not responded to treatment and has spread to soft tissues (extramedullary disease). The goal is to make the CAR-T therapy work better.
BeijingAges 18 years+ - NCT07784309Enrolling by invitationPhase 1
Cell therapy for CD7-positive blood cancer
This study tests a new cell therapy for people with certain types of blood cancer that have returned or not responded to standard treatments. The therapy uses immune cells modified to target a marker called CD7 on cancer cells. It may help reduce or eliminate the cancer.
TianjinAges 3–70 - NCT07409454RecruitingPhase 2
Post-transplant treatment for multiple myeloma with a bispecific antibody
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
TianjinAges 18 years+
Hear when a new Hematologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematologic diseases?
- Yes. Clin2 currently lists 238 recruiting hematologic diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematologic diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematologic diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.